Related Experiment Videos
[New pharmaceuticals in systemic mycoses (author's transl)]
Zeitschrift Fur Hautkrankheiten
|September 1, 1981
Summary
Systemic fungal infection treatment is challenging due to limited drug options. This review discusses the properties of existing antifungal agents and the newer imidazole derivative, Ketoconazole.
Area of Science:
- Mycology
- Pharmacology
- Infectious Diseases
Context:
- Systemic fungal infections pose significant therapeutic challenges.
- Limited availability of effective antifungal agents restricts treatment options.
Purpose:
- To review the primary antimycotic and pharmacokinetic properties of key antifungal drugs.
- To discuss the role and characteristics of Ketoconazole, a newer imidazole derivative.
Summary:
- Current antifungal chemotherapy relies on Amphotericin B, 5-Fluorocytosine, and intravenous Miconazole.
- Experience with Ketoconazole, a novel imidazole antifungal, is still developing.
- The review covers essential properties of these agents for treating systemic mycoses.
Impact:
- Provides a concise overview of antifungal drug profiles for clinicians and researchers.
- Highlights the need for and potential of new antifungal agents like Ketoconazole.
- Aids in understanding treatment options for difficult-to-treat systemic fungal infections.